

Treatment of bioresorbable scaffold failure

CM Felix, BRC Everaert, N Jepson, C Tamburino, RJM van Geuns

Eurointervention. 2015 May 9

INTRODUCTION

Bioresorbable scaffolds (BRS) are a promising new interventional treatment strategy for coronary artery disease. They were developed to overcome some of the limitations of metal drug-eluting stents (DES), mainly the late reinterventions which occur at a consistent rate after one year and have not been reduced by use of local drug-elution. Initial experience in non-complex lesions established the efficacy in opening the vessel and the concept of bioresorption. However, with the use of BRS in more complex lesions, also the incidence of BRS failure, including both scaffold restenosis and thrombosis (ScT), has increased. Therefore, both understanding of the pathophysiology and of the available treatment options of scaffold failure remain important issues in insuring procedural and long-term clinical success.

Over the past years, bioresorbable scaffolds (BRS) have evolved as the new treatment strategy for coronary artery disease (CAD) with the Absorb bioresorbable vascular scaffold (BVS, Abbott Vascular, Santa Clara, California, USA) being the device most intensively studied.

A different CE marked scaffold, the DESolve myolimus-eluting bioresorbable coronary scaffold system (Elixir Medical Corporation, Sunnyvale, CA, USA) is currently under investigation. [1]. Although the DESolve is also PLLA based the degradation and drug-elution profile is different and different timings for failure strategies may apply. Recently, the Magmaris scaffold (Biotronik AG, Bülach, Switzerland. Previously known as DREAMS scaffold), a sirolimus eluting and magnesium based scaffold, received CE mark after its safety was tested in the BIOSOLVE-II first-in-man trial. [2] Resorption is faster than in PLLA based scaffolds. For both scaffolds, very little is known about the performance in real-world patients.

Invasive imaging at two years demonstrated that BVS are largely absorbed and late lumen enlargement occurred. In this way, BRS offer transient vessel support to prevent acute vessel recoil during angioplasty while eluting an antiproliferative drug to minimize neointima hyperplasia during the healing process. Multiple randomized controlled trials (ABSORB EXTEND, ABSORB II, ABSORB III, ABSORB China and ABSORB Japan) in non-complex patients showed results comparable to cobalt-chromium based everolimus eluting Xience V metal stent (CoCr-EES; Abbott Vascular, Santa Clara, CA, USA). [3-6] It should be underlined that only lesions of moderate complexity were included in these RCT's. In more real world lesion registries [7-13] BVS failure (including both scaffold thrombosis (ScT) and scaffold restenosis (Figure 1) occurs regularly and implantation of BVS in more complex patients seems to be associated with a higher rate of adverse events. In this chapter we will give a short overview of the pathophysiology and the treatment options in case of BRS failure.




Figure 1 Edge restenosis treated with Absorb BVS.

A 65-year-old male patient presenting with an NSTEMI was treated with a 3.5×28 mm Absorb BVS for a trifurcation lesion of the LAD and two diagonals (A & B). He returned 142 days later for unstable angina due to a subtotal occlusion of the LAD with slow flow distal to the scaffold (TIMI 1) (C). OCT imaging revealed edge restenosis as the underlying mechanism for BRS failure (D) and restenosis within the scaffold with a layered pattern (E), but no luminal thrombus. The patient was treated with thrombus aspiration and a 3.5×38 mm DES (PROMUS™; Boston Scientific, Marlborough, MA, USA). A retrospective review of the post-procedural angiogram at baseline showed proximal edge dissection (B) and incomplete lesion coverage with geographic miss as the reason for restenosis (F series). Black arrows indicate the scaffold markers and white arrows the uncovered edge segment. Adapted from Antonis Karanasos et al; Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis. A single-center experience. (Accepted and in press *Circ Cardiovasc Interv* 2015).

Risk factors for scaffold restenosis

The mechanism for BMS or DES restenosis is multifactorial and consists of stent recoil, formation of neointima, organization of thrombus, geographical miss and vessel remodeling. The pivotal factor in the process of ISR is neointimal formation, due to migration and proliferation of smooth muscle cells and myofibroblasts. In the long-term, metallic DES might fracture at hinging points in the coronary artery inducing an inflammatory reaction. Occasionally, some patients seem to be 'limus' resistant and develop early restenosis (Figure 2). [14] Finally, negative remodeling of the vessel contributes to the restenosis process. [15]




Figure 2 Absorb BVS and neointimal hyperplasia treated with DES, and recurrent failure.

A 59-year-old male patient was treated with one Absorb BVS (3.5×28 mm) in the proximal LAD for unstable angina (A-C). The patient developed an NSTEMI 112 days after the index PCI with TIMI 1 flow (D) and was therefore classified as a definite ST. OCT showed mild scaffold underexpansion (3 mm diameter) with severe neointima development (D' and D'') but also areas with late malapposition and potential vasodilatation and thrombus resorption (D'). Treatment consisted of thrombectomy, eptifibatide and a 3.5×32 mm DES (PROMUS; Boston Scientific) followed by post-dilatation with 4.0 mm balloon, the lumen increased significantly and malapposition was resolved on OCT (E') with good angiographic results (E). The patient returned almost four months later with unstable angina. There was a severe ISR on angiography (F) with total occlusion (arrow) and collateral flows suggesting a resistance to the "limus" drugs used. It was decided to perform a semi-urgent CABG, which took place four days later.

The rates of BMS-ISR have been described to be as high as 60%, depending on several risk factors such as lesion complexity, patient co-morbidities and vessel size. [16-19] The use of DES has significantly reduced the rate of ISR, although DES-ISR rates at one year have been stated to occur in 3% - 20% of the patients, depending on DES generation and patient, lesion and procedural characteristics. [20]

Multiple patient, lesion and procedure-related risk factors for ISR in BMS and DES have been reported, including diabetes mellitus, multi-vessel disease, stent length, bifurcation lesions, small caliber vessels, chronic total occlusion (CTO), strut thickness, usage of multiple stents and stent underexpansion. Hypersensitivity reaction to the polymer is another important mechanism. ISR by itself is also a predictor for future ISR. [20-25]

Also the stent type plays an important role which can be related to strut thickness, drug dosage and drug release profile. In general, thicker stent struts cause more flow disturbances with reduced endothelial shear stress [26], which does enhance the process of neointimal hyperplasia.

It seems likely that most risk factors for ISR with BRS are the same as for ISR with BMS or DES; however, at this moment, there is little evidence to confirm this presumption. Recently, a case series reported on geographical miss and scaffold underexpansion as being the most frequent causes of BRS failure. [27]

Risk factors for scaffold thrombosis

Several risk factors for ST exist. Many of them are also predictive for stent restenosis. These risk factors can be categorized as lesion, patient and procedure-related factors. Procedure-related factors are stent malapposition, stent undersizing, dissection, placement of multiple stents, stent overlap and stent length. Lesion-related factors include coronary bifurcations, heavily calcified lesions, long lesion length, small vessel size and CTO. Finally, there are the patient-related factors such as diabetes mellitus, advanced age, renal failure, low ejection fraction, smoking, prior CABG, acute coronary syndromes (ACS) at presentation, (early) discontinuation of DAPT or resistance to clopidogrel. [28, 29]

Probably, and in line with DES, the rate of ScT varies depending on lesion, patient and procedure-related characteristics. The most remarkable difference between BVS and current DES is the increased strut thickness and width (comparable to old stainless steel BMS and first generation DES). This will increase the early uncovered surface significantly. Also, strut thickness induces convective flow patterns, triggering platelet deposition. [30] Susceptibility to platelet aggregation might further aggravated be in conditions such as scaffold underexpansion, treatment of thrombotic lesions, e.g. during ACS, and DAPT interruption.

Scaffold underexpansion is an important issue in BVS [31] and is an important contributor to BRS failure. It occurs less if lesions are treated using an optimal implantation strategy. Starting with the use of a non-compliant balloon with the same size as RVD and with a 1:1 ratio to the vessel, full expansion of the scaffold and with the same size as RVD and post-dilatation with a non-compliant balloon up to a maximum of 0.5mm larger. [32, 33] Discontinuation of DAPT and edge dissections have also been described as causes of Sct. [34] Currently ongoing and future all-comer, randomized controlled trials will indicate whether BRS have more favorable rates of late ScT compared to the current generation DES.

Scaffold dislodgement

In severely calcified or tortuous lesions, successful delivery of BRS can be difficult and the scaffold could be potentially dislodged [35] in the same way as metallic stents.

However after an early publication, no further cases of scaffold dislodgement have been reported anymore.

Incidence of scaffold failure in BVS studies and registries

Little is known about the exact incidence of ST and ISR with the use of BRS and in most publications the cause of BRS failure, whether by ScT or ISR, is not clearly reported.

The ABSORB II study reported a TLR rate at one year of 1% in the BRS group compared to 2% in the Xience group. [3] Twelve month TLR rate in ABSORB III was 3.0% (vs 2.5% in the Xience group). [5] The five year TLR rate in low risk patients and non-complex lesions of the ABSORB Cohort A study was 3.4% [36], whereas the TLR rate of an everolimus-eluting stent (EES, Xience V) at five years was 8.6% in the SPIRIT III trial. [37]

Wohrle et al. reported on the one year outcomes of the ASSURE registry: five cases of TLR (2.8%) occurred, all due to ISR. Treatment options used were DEB (two patients with long lesions in small vessels, treated with overlapping BRS), DES (ISR of a saphenous vein graft due to malapposition of the BRS), POBA (for incomplete (proximal) BRS expansion) and CABG (total occlusion of the target vessel). [8]

The GHOST-EU trial, including 1189 patients, showed a TLR rate of 2.5% at six months and target lesion failure (TLF: a composite of cardiac death, target-vessel myocardial infarction or ischemia-driven target-lesion revascularization) rate of 4.4% at six months. In a multivariate analysis, TLF was seen more in patients with diabetes and in smokers, however this was not statistically significant. [7]

Ishibashi et al. summarized the rates of BVS ST reported in multiple trials. The incidence of ST varied from 0 up to 3.0% in a time period ranging from one to six months [38]. In another recent review article the number of definite ST ranged from 0% at one year to 3.2% at six months. [39]

Most cases of BRS-ST occur within the first 30 days after implantation; however some cases of late ST were also described. The cumulative incidence of ST at six months was 2.1% in the GHOST-EU trial. In 13% of the cases there was DAPT discontinuation. Other possible causes are the low rate of post-dilatation and little usage of invasive imaging in B2/C lesions. [7]

Regarding the first 450 patients enrolled in the ABSORB Extend trial, seven cases of BRS failure occurred, i.e. three cases (0.67%) of scaffold dislodgement and four cases of ST (0.89%). [35]

Of the 101 patients included in the BVS Cohort B trial, only six cases of ISR occurred (5%) during a three year follow-up period. The mechanisms for ISR were procedural edge injury during the initial procedure, geographical miss, and in one case myocardial bridging. In three cases the cause of ISR could not be identified. [40]

The BVS Expand single-center registry (excluding STEMI patients) reported a definite ScT rate at 18 months of 1.9% and a TLR rate of 4.0%. [9] The mid-term outcomes of the

BVS STEMI First registry (including only STEMI patients) showed a high rate of definite Sct (4.3%), mainly caused by procedural factors, and TLR (5.7%). [10]

The Amsterdam ABSORB registry, reporting on complex lesion (AHA/ ACC lesion classification B2/C in 67%), revealed a one-year TLR rate of 8.9% and 11.4% at two years. [13] One-year TLR rate from the Polish National Registry, including both stable and ACS patients, was 1.5%. [41]

Summarized, TLR rates can be as high as 8.9% at one year, depending on lesion and patient complexity. BRS failure can be caused by geographical miss, scaffold dislodgement, scaffold malapposition and underexpansion, lesion length and DAPT discontinuation.

How to treat BRS failure

Multiple treatment options for treating BRS failure exist: thrombus aspiration, balloon angioplasty (POBA), BMS, DES, BRS, drug-eluting balloons (DEB) or medical treatment (e.g. with a thrombolytic agent or a glycoprotein IIb/IIIa inhibitor (GPI)). Deciding which is most suitable depends on the triggering mechanism and not infrequently multiple underlying factors are present. Understanding the fundamental pathophysiological mechanism underlying the TLF is of key importance to direct subsequent management. Invasive imaging modalities, such as optical coherence tomography (OCT) are of paramount importance to achieve treatment success. OCT enables the operator to determine between the different mechanisms for BRS-TLF such as scaffold underexpansion, scaffold malapposition or undersizing, geographic miss (edge dissection, edge restenosis), neointimal hyperplasia or scaffold strut fracture.

BRS thrombosis after DAPT interruption, whether acute (<24 hours,) subacute (<1 month) or late, can be managed with the use of thrombectomy, GPI and/or POBA. In patients on clopidogrel that present with an occlusion of the target vessel due to a thrombus, platelet function testing and switching to more potent P2Y₁₂ inhibitor has to be considered.

Early underexpansion and malapposition can be treated with POBA with non-compliant balloons in a 1:1 balloon – vessel ratio and with sufficient diameter and pressure, although the maximum overexpansion limit of 0.5 mm always has to be respected for BVS, especially in the situation of undersizing (Figure 5). If the vessel is above 4 mm in diameter and there is serious malapposition, large metallic stents are indicated. Preferably a DES is used, although potentially a BMS could be sufficient for treatment of acute or subacute (<30 days) scaffold failure. However, the negative effects of an additional dose of antiproliferative drugs when DES are used seem only theoretical and hence not of clinical importance. If underexpansion cannot be managed by POBA alone, a BMS or DES is indicated to ensure additional radial support (Figure 3). To minimize stent overlap, only the insufficiently apposed areas needed be covered with the new stent. After thirty days we strongly recommend DES (or even second BVS in larger vessels) as the




Figure 3 Absorb BVS failure due to discontinuation of DAPT treated with thrombus aspiration and POBA. A 60-year-old male patient with a history of smoking, hypertension and heart failure presented with stable angina. There was one-vessel disease and a LAD, 1 diagonal, lesion (Medina 0,0,1) on angiography. A) Two 3.0x12 mm Absorb BVS were placed in the LAD and 1st diagonal, using the T and protrusion technique with good results in the spider (B) and RAO (C) projections. After 129 days the patient developed a STEMI due to an occluded LAD (D) potentially due to ascal and prasugrel discontinuation for CVA. POBA with a 3.0 mm balloon was then performed. After three AngioJet (Boston Scientific) runs, the angiographic result was acceptable (E) and eptifibatide was continued for 24 hours. The treatment of BRS failure was reviewed four days later using OCT (F-M). Pullback from the LAD (lower row) showed some remaining thrombus (H), and signs of fractures or double layer of uncovered struts (I, arrow). Pullback from the diagonal branch showed some undersizing distal (J) and some double layer and lost struts (K, arrow). Proximal to the bifurcation the struts were well apposed and mainly well covered (L and M).

remaining dose of everolimus on the BVS might not be sufficient to effectively reduce neointimal hyperplasia (Figure 3). For undersizing, POBA could be sufficient up to six months as the goal is ensuring optimal apposition without further vessel dilatation (low pressure) inducing a new healing process.

After approximately six months the tie chains between the crystal polylactide lamellae become more and more hydrolyzed and the radial strength and subsequent vessel support gradually decreases (Figure 4). [42] BRS failure after six months due to mechanical problems will need placement of an additional stent or scaffold.




Figure 4 Scaffold thrombosis due to underexpansion treated with DES.

A 69-year-old male patient presented with an NSTEMI. Angiography showed one-vessel disease with long narrowing of the proximal and mid LAD and collateral filling (A). Three Absorb BVS (3.0×28 mm, 3.5×18 mm, 3.5×18 mm) were implanted (D). After placement of the first two scaffolds there was compression and thrombus in the 1 diagonal. Invasive imaging post procedure revealed organised thrombus behind the struts of the proximal scaffold (B: IVUS) and thrombus protrusion at the overlapping scaffolds (C: OCT). After 47 days the patient presented with a non-Q-wave myocardial infarction due to a full occlusion in the proximal LAD (E). There was some underexpansion, but a large thrombus on OCT (F). He was treated with thrombectomy, eptifibatide and PCI with a 3.5×38 mm DES (XIENCE) covering the proximal BVSs with a good angiographic and OCT result (G & H). The control diagnostic angiography made 110 days later (I) displayed good scaffold and stent apposition on OCT with good coverage of the struts of the new DES (J) and the untreated original distal Absorb BVS (K).

In the setting of a geographical miss leading to a clinically relevant acute or subacute edge dissection, a BRS bailout strategy could be used. In case of a geographical miss with apparent edge restenosis, placement of an additional BRS is possible although converting to DES with a minimal risk of repeat ISR is more prudent. ISR due to intimal hyperplasia can be treated by a DEB (<6 months) but after 6 months, additional vessel support is indicated (with a preference for DES) (Figure 1).

Lastly, in the case of limited scaffold strut fracture, POBA should be able to correct the malapposed segments [43]. For more extensive fractures or large diameter vessels, a new stent (BMS or DES) would be the treatment of choice. Again, after six months disintegration of the scaffold is initiated and additional radial strength is necessary (DES preferred). In case of both fracture and underexpansion, lesion dilatation is necessary and we recommend an additional DES from thirty days after the initial BRS placement. Treatment options for BRS failure are summarized in table 1.

Table 1. Treatment options for BRS failure.

	Acute (< 24 h)	Subacute (< 30 days)	Late (< 6 months)	Very late (> 6 months)
DAPT interruption	GPI/ thrombectomy/POBA			
Underexpansion	POBA		DES/ BVS	
Undersizing/ Malapposition	POBA: max 0.5mm > nominal > 4mm: DES/ BMS*			DES/ BVS
Geographical miss	Dissection: BVS bailout		Edge stenosis: DES/ BVS	
Neointimal hyperplasia	--		DEB	DES/ BVS
Strut fracture	POBA: max 0.5 > nominal > 4mm: DES/ BMS*			DES

*In the first period, as drug release is still ongoing, BMS theoretically should be sufficient

However, we have to mention that most of the clinical experience with BRS failure is gained from the experience with the Absorb BVS platform, and that, given the paucity of trial numbers, only few data are available for other BRS subtypes such as the DESolve novolimus-eluting bioresorbable coronary scaffold system (Elixir) or metal-based (magnesium) resorbable devices. As such, these recommendations for the treatment of BRS failure are only applicable to the Absorb BVS.

CONCLUSION

Treatment of scaffold failure should target any suboptimal result. After thrombus aspiration and aggressive medical treatment, intravascular imaging is advised to reveal any scaffold abnormalities. A wide range of strategies can be applied to correct suboptimal scaffold results. The major difference between BRS and DES in the treatment of target lesion failure is the more frequent need for additional vessel support (using a second BRS or a DES).




Figure 5 Bioresorption of Absorb BVS. Initially, cleavage of polylactides results in minimal molecular weight loss with remaining full support until six months.

After six months, degradation significantly impacted on tie chains between crystal lamellae occurs rapidly, reducing radial support when the material starts to become brittle. Implantation of additional vessel supportive therapy is indicated to successfully treat lumen reduction. Adapted from Serruys et al (34).

REFERENCES

1. Verheye, S., et al., A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. *JACC Cardiovasc Interv*, 2014. 7(1): p. 89-99.
2. Haude, M., et al., Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. *Eur Heart J*, 2016.
3. Serruys, P.W., et al., A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. *Lancet*, 2014.
4. Abizaid, A., et al., The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. *EuroIntervention*, 2014.
5. Ellis, S.G., et al., Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. *N Engl J Med*, 2015.
6. Gao, R., et al., Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease: ABSORB China trial. *J Am Coll Cardiol*, 2015.
7. Capodanno, D., et al., Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. *EuroIntervention*, 2014.
8. Wohrle, J., et al., Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. *EuroIntervention*, 2014.
9. Felix, C.M., et al., Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry. *JACC Cardiovasc Interv*, 2016.
10. Fam, J.M., et al., Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. *EuroIntervention*, 2016. 12(1): p. 30-7.
11. Miyazaki, T., et al., Clinical outcomes following "off-label" versus "established" indications of bioresorbable scaffolds for the treatment of coronary artery disease in a real-world population. *EuroIntervention*, 2016. 11(13): p. 1475-8.
12. Felix, C.M., et al., Are BVS suitable for ACS patients? Support from a large single center real live registry. *Int J Cardiol*, 2016. 218: p. 89-97.
13. Kraak, R.P., et al., Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria. *EuroIntervention*, 2016. 12(5): p. e557-65.
14. Lemos, P.A., et al., Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. *Circulation*, 2003. 108(3): p. 257-60.
15. Kibos, A., A. Campeanu, and I. Tintoiu, Pathophysiology of coronary artery in-stent restenosis. *Acute Card Care*, 2007. 9(2): p. 111-9.
16. Serruys, P.W., et al., A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. *N Engl J Med*, 1994. 331(8): p. 489-95.

17. Babapulle, M.N. and M.J. Eisenberg, Coated stents for the prevention of restenosis: Part I. Circulation, 2002. 106(21): p. 2734-40.
18. Fischman, D.L., et al., A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med, 1994. 331(8): p. 496-501.
19. Greenberg, D., A. Bakhai, and D.J. Cohen, Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol, 2004. 43(4): p. 513-8.
20. Dangas, G.D., et al., In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol, 2010. 56(23): p. 1897-907.
21. Hoffmann, R., et al., Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation, 1996. 94(6): p. 1247-54.
22. Hoffmann, R. and G.S. Mintz, Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J, 2000. 21(21): p. 1739-49.
23. Farooq, V., B.D. Gogas, and P.W. Serruys, Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv, 2011. 4(2): p. 195-205.
24. Weintraub, W.S., The pathophysiology and burden of restenosis. Am J Cardiol, 2007. 100(5A): p. 3K-9K.
25. Kimura, T., et al., Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation, 2012. 125(4): p. 584-91.
26. Bourantas, C.V., et al., Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study. JACC Cardiovasc Interv, 2014. 7(3): p. 315-24.
27. Longo, G., et al., Anatomical Features and Management of Bioresorbable Vascular Scaffolds Failure: A Case Series from the GHOST Registry. Catheter Cardiovasc Interv, 2015.
28. Iakovou, I., et al., Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama, 2005. 293(17): p. 2126-30.
29. Machecourt, J., et al., Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol, 2007. 50(6): p. 501-8.
30. Duraiswamy, N., et al., Effects of stent geometry on local flow dynamics and resulting platelet deposition in an in vitro model. Biorheology, 2008. 45(5): p. 547-61.
31. Karanasos, A., et al., Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv, 2015. 8(5).
32. Brown, A.J., et al., Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv, 2014. 84(1): p. 37-45.
33. Puricel, S., et al., Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. J Am Coll Cardiol, 2016. 67(8): p. 921-31.
34. Azzalini, L. and P.L. L'Allier, Bioresorbable vascular scaffold thrombosis in an all-comer patient population: single-center experience. J Invasive Cardiol, 2015. 27(2): p. 85-92.
35. Ishibashi, Y., et al., Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention, 2014. 10(4): p. 449-57.
36. Onuma, Y., et al., Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv, 2013. 6(10): p. 999-1009.

37. Gada, H., et al., 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). *JACC Cardiovasc Interv*, 2013. 6(12): p. 1263-6.
38. Ishibashi, Y., S. Nakatani, and Y. Onuma, Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients. *EuroIntervention*, 2014.
39. C.M. Felix, B. Everaert, R. Diletti, N.M. Van Mieghem, J. Daemen, M. Valgimigli, P.P. de Jaegere, F. Zijlstra, E. Regar, C. Simsek, Y. Onuma, R.J.M. van Geuns, Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. *Neth Heart J*, 2015.
40. Nakatani, S., et al., Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. *EuroIntervention*, 2014.
41. Rzeszutko, Ł., et al., Twelve months clinical outcome after bioresorbable vascular scaffold implantation in patients with stable angina and acute coronary syndrome. Data from the Polish National Registry. *Postępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology*, 2016. 12(2): p. 108-115.
42. Serruys, P.W., et al., Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. *J Am Coll Cardiol*, 2011. 58(15): p. 1578-88.
43. Pan M, R.M., Ojeda S, Suarez De Lezo Jr J, Segura J, Mazuelos F, Lopez J, Martin P, Medina A, Suarez De Lezo J, Rupture of bioresorbable vascular scaffold after side-branch dilation in bifurcation lesion. *Eur Heart J*, 2014. 35 (Abstract Supplement)(12).